ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2581

Tripterygium Wilfordii Hook F Applied Topically in Patients with Active Rheumatoid Arthritis

Juan Jiao1, Hai-bo Yin2, Xiao-po Tang2, Xun Gong2 and Quan Jiang1, 1Rheumatology Department, Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China, 2Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: rheumatoid arthritis, treatment

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 15, 2016

Title: Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster III

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose:  Tripterygium wilfordii Hook F (TwHF), a traditional Chinese herb, is widely used in China for treating Rheumatoid Arthritis (RA), but limited only for eldly RA patients because of its reproductive system toxicity. We were inspired by external therapy, an immemorial therapy for thousands of years, and took its advantage to make TwHF topically in order to get an effective and safe treatment for active RA patients.

Methods: In this 4-week double-blinded, randomized, placebo controlled clinical trial, patients were 1:1 randomized to add-on topical TwHF twice a day or placebo for 4 weeks. The primary endpoint was the rate of achievement of 20% improvement in the American College of Rheumatology criteria (ACR20) at week 4. Secondary endpoints were 50% improvement in the ACR criteria (ACR50), 28-joint count Disease Activity Score (DAS28) improvement and safety profiles. Statistical analyses were performed using intention to treat analysis (ITT) set.

Results:  A total of 70 active RA patients were enrolled. At week 4, the ACR20 was 34.3% (12/35) in topical TwHF group and 11.4% (4/35) in placebo group (P=0.015). Similarly, a higher ACR50 responder proportion was seen in topical TwHF group with 17.1% (6/35) comparing to it in placebo group with 2.9% (1/35) (P=0.046). The topical TwHF group also had more improvement than the placebo group on DAS28-ESR (1.1 vs 0.5, P=0.001), DAS28-CRP (1.4 vs 0.7, P=0.001), tender joint count (5.5 vs 2.6, P=0.018), swollen joint count (3.5 vs 1.6, P=0.003) and Physician’s global assessment (25.8 vs 13.0, P=0.002), as well as C-reactive protein (11.2 vs 2.7, P=0.048). Initial effect onset time of pain and swelling reductions were significantly shorter in topical TwHF group with Means of both 7 days (range: 2.5 hours to 11 days and 1 to 21 days, respectively) than those of 11 and 17 days (range: 4 to 24 days and 4 to 28 days, respectively) in placebo group (P=0.022, P<0.001), respectively. There were 2 adverse slight skin allergy events in topical TwHF group. No substantive differences in adverse events were observed.

Conclusion:  Topical TwHF is an effective and safety complimentary treatment in patients with active RA.


Disclosure: J. Jiao, None; H. B. Yin, None; X. P. Tang, None; X. Gong, None; Q. Jiang, None.

To cite this abstract in AMA style:

Jiao J, Yin HB, Tang XP, Gong X, Jiang Q. Tripterygium Wilfordii Hook F Applied Topically in Patients with Active Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/tripterygium-wilfordii-hook-f-applied-topically-in-patients-with-active-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/tripterygium-wilfordii-hook-f-applied-topically-in-patients-with-active-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology